Dr. Todd Lanman Presents the Latest Developments in Lumbar Facet Replacement and Periprosthetic Osteolysis Management, 7-Year M6-C IDE Results at ISASS23
SAN FRANCISCO, June 12, 2023 (Newswire.com)
-
Todd Lanman, MD, of Lanman Spinal Neurosurgery and ADR Spinal Restoration Center, gave several presentations on each of the three days of the 23rd Annual International Society for the Advancement of Spine Surgery Conference (ISASS23) Meeting in San Francisco, California.
In the first session of the conference, Dr. Lanman made a compelling case for why spine surgeons need to have the ability to provide patients with lumbar facet replacement. He presented cases that demonstrate how patients are severely affected by lumbar facet disease, spinal stenosis, and spondylolisthesis from L2 to L5. Dr. Lanman went on to describe how the Total Posterior Spine (TOPS™) system, now approved in Europe, is making lumbar facet replacement a reality and greatly improving the lives of patients. Dr. Lanman suggests that total posterior spinal arthroplasty will gradually eclipse spinal fusion for many cases of spondylolisthesis, just as artificial disc replacement has eclipsed fusion for intervertebral disc diseases.
This talk was followed by a panel discussion that included Drs. Todd Lanman, Harel Deutsch, Roland Kent, and Luis Manuel Tumialán.
On the second day of ISASS23, Dr. Lanman reviewed the clinical and radiographic findings associated with periprosthetic osteolysis. In this rare complication of cervical disc replacement, the bone surrounding the implant degenerates. This bone breakdown may loosen the artificial disc, causing pain and dysfunction. Dr. Lanman recommended ways to clinically manage this unusual complication.
On the last day of the conference, Dr. Lanman presented 7-year Investigational Device Exemption (IDE) trial results of the M6-C cervical disc replacement device. Like other cervical disc trials, artificial disc replacement with M6-C is superior to anterior cervical discectomy and fusion (ACDF) in reducing pain and neck disability. Reoperations rates are similar to other commercially-available artificial discs.
About Dr. Todd Lanman:
Todd Lanman, MD has over three decades of experience as a spinal neurosurgeon and has spent the last 25 years practicing spine surgery in Beverly Hills. In addition to being a world-renowned spinal surgeon, Dr. Lanman has also had 11 spinal surgeries, including spinal fusions and artificial disc replacements. Because of these experiences as a surgeon and as a patient, Dr. Lanman brings a unique perspective to his surgical practice.
About Lanman Spinal Neurosurgery:
Lanman Spinal Neurosurgery is committed to improving patients' quality of life by relieving pain and restoring spinal motion. The Beverly Hills practice has been at the leading edge of spine health for the past quarter of a century and most recently expanded nationwide with the Artificial Disc Replacement Spinal Restoration Center. Lanman Spinal Neurosurgery has and continues to pioneer artificial disc replacement and fusion revision surgeries to help neck and back pain sufferers live their best lives.
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacologythat demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026.
"Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson's disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease," said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. "This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics."
For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson's disease was performed at Chaminade University (Honolulu, Hawai'i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson's disease at the National Research Council of Canada (NRC). The study entitled "Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson's disease" was co-authored by Gb Sciences' own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai'i at Manoa (Manoa, Hawai'i, USA).
The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving "relative" simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of insilico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
